Easton Pharmaceuticals Announces Signing LOI for Joint Venture Towards Private Medical Marijuana Colorado Grower & Licenses; ...
28 Marzo 2014 - 3:44PM
Marketwired
Easton Pharmaceuticals Announces Signing LOI for Joint Venture
Towards Private Medical Marijuana Colorado Grower and Licenses;
Provides Clarification on Its Canadian Medical Marijuana
Initiatives
TORONTO, ON--(Marketwired - Mar 28, 2014) - Easton
Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical
company that owns, designs, develops, and markets an array of
topically-delivered drugs and therapeutic / cosmetic healthcare
products, today announces it has signed a letter of intent for the
creation of a possible JV with another US company towards a Private
Medical Marijuana company in the state of Colorado.
The Letter Of Intent was signed with another public company
listed on the OTCQB exchange. Easton has engaged an attorney who
for the past few days and moving forward will perform due diligence
on the company and most importantly the licenses this company has
claimed it has rights to through a private Colorado grower in the
state of Colorado. The LOI calls for a joint venture where both
Easton and the other company would either purchase an interest in
or finance the operations in the private Colorado grower. Any
closing is contingent on the satisfaction of the due diligence by
Easton's attorney and its negotiations with the other company's
attorney or representatives. Easton Pharmaceuticals, or any other
company or principles not having residence in the state of Colorado
for more than 2 years, cannot entirely own all the assets in any
medical marijuana companies within the state of Colorado. Any
negotiations must satisfy these requirements. No time frames have
yet been set.
Easton also wishes to clarify the misinformation regarding its
Canadian medical marijuana initiatives. Although the company has
still not signed a final agreement regarding any of its Canadian
medical marijuana initiatives which is as a result of various
reasons it is currently unable to disclose, this by no means
signifies that it has ended any negotiations with any other
companies previously disclosed. No other companies including
current growers in B.C. have closed any transactions with any other
companies and still maintain discussions with Easton
Pharmaceuticals which included a personal meeting with all
principals in the past few days. This also includes negotiations
with another public company listed on the OTCQB exchange where
another joint venture is being contemplated towards medical
marijuana assets situated in Ontario Canada.
About Easton Pharmaceuticals Easton Pharmaceuticals is a
specialty pharmaceutical company involved in various industries
including medical marijuana that also owns, designs, develops, and
markets topically-delivered drugs and therapeutic / cosmetic
healthcare products, focused on cancer and other health issues
related towards male and female sexual dysfunction, wound healing,
pain, motion sickness, scar and stretch marks, cellulite, varicose
veins and other conditions. The company's gel formulation is
thought to be an innovative and unique transdermal delivery system.
Easton Pharmaceuticals' product "VIORRA" is an
over-the-counter aid for the treatment to restore and improve
vaginal moisture and elasticity which is believed to have a
positive effect on women's sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder); the world market for these female
conditions is conservatively estimated to be in the billions.
VIORRA is a topical, daily-use product classified by the
FDA as containing Generally Recognized as Safe
ingredients.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "anticipate," "pleased," "plan," "confident
that," "believe," "expect," "possible" or "intent to" and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the
safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. There are no guarantees that any proposals, initiatives
or negotiations will result in a deal acceptable to the company.
Any investment made into Easton Pharmaceuticals would be classified
as a risky investment. Such risks and uncertainties include, but
are not limited to, market conditions, general acceptance of the
company's products and technologies, competitive factors, the
ability to successfully complete additional or adequate financing,
government approvals or changes to proposed laws and other risks
and uncertainties further stated in the company's financial reports
and filings.
Contact: Carla Pepe Easton Pharmaceuticals Inc. Tel: +1(416)
619-0291 Tel: +1(347) 284-0192 email:
info@eastonpharmaceuticalsinc.com email:
info@ashleybiomedical.com
Grafico Azioni Easton Pharmaceuticals (CE) (USOTC:EAPH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Easton Pharmaceuticals (CE) (USOTC:EAPH)
Storico
Da Giu 2023 a Giu 2024